Previous studies have demonstrated that, during treatment with EGFR inhibitors, cancer cells can acquire somatic mutations in the EGFR gene, significantly reducing the drugs’ affinity for EGFR (Rosell et al., 2009; Yu et al., 2014; Sattler et al., 2023; Tomuleasa et al., 2024). The gene discussed is EGFR; the disease is cancer.